Tuesday, April 25 at 9:00 AM–10:30AM ET
Despite a dynamic research and development (R&D) pipeline for prevention products, male and female condoms remain the only multi-purpose prevention technologies (MPTs) currently available. Yet MPTs are an integral part of the HIV prevention advocacy agenda. For decades, advocates have pushed for products to be developed that simultaneously prevent HIV, other sexually transmitted infections (STIs) and/or pregnancy.
With a growing number of PrEP options already, what will it take to bring a new MPT to market? A Dual Prevention Pill (DPP – https://www.prepwatch.org/products/dual-prevention-pill/) that prevents both HIV and pregnancy could be just two years away. Looking further upstream, there are over 25 other MPTs in the pipeline (https://www.prepwatch.org/research-pipeline/), including vaginal rings, which would follow in the footsteps of the dapivirine vaginal ring recommended by WHO and recently approved in several countries.
Within this fast-evolving HIV prevention landscape, work is already underway to build a platform to introduce the DPP, which could speed up the rollout of other MPTs. Join us to hear what we’ve learned so far on R&D, marketing, counseling and delivery for MPTs – and to discuss what we can do now to prepare prevention markets to include new MPT options.
Featured Speakers:
Ruth Akulu, ICWEA, AVAC fellow
Barbara Friedland, Population Council
Gregorio Millet, amfAR
Dr. Thesla Palanee-Phillips, Wits RHI
Danielle Resar, Clinton Health Access Initiative
Co-moderators: Wawira Nyagah, AVAC Kate Segal, AVAC
This webinar is a part of The Choice Agenda.